High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum

被引:143
作者
Tournel, G
Houdret, N
Hédouin, V
Deveaux, M
Gosset, D
Lhermitte, M
机构
[1] Univ Lille 2, Inst Med Legale Lille, Fac Med, F-59000 Lille, France
[2] Hop Calmette, Toxicol Lab, F-59000 Lille, France
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 761卷 / 02期
关键词
fluvoxamine; milnacipran; paroxetine; sertraline; fluoxetine; citalopram; venlafaxine;
D O I
10.1016/S0378-4347(01)00305-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A high-performance liquid chromatographic screening method (HPLC) is described for the determination of seven selective serotonin reuptake inhibitors (SSRIs) (fluvoxamine, milnacipran, paroxetine, sertraline, fluoxetine, citalopram, venlafaxine) and for three pharmacologically active N-demethylated metabolites (desmethylcitalopram, didesmethylcitalopram and norfluoxetine). A tricyclic antidepressant, clomipramine, was used as an internal standard. The method consists of liquid extraction of serum after alcalinisation at pH 9.50, followed by chromatography on a Beckman C-18 reversed-phase column. Compounds were detected at 200.4 nm. The standard curves were linear over a working range of 50-1000 ng/ml for fluvoxamine, 15-1000 ng/ml for fluoxetine, 25-500 ng/nd for norfluoxetine, 50-500 ng/ml for sertraline, 20-500 ng/ml for paroxetine, 25-550 ng/ml for citalopram, 25-750 ng/ml for desmethylcitalopram, 25-800 ng/ml for didesmethylcitalopram, 25-650 ng/ml for milnacipran, and 25-500 ng/ml for venlafaxine. The quantitation limits of the method were 15 ng/ml for fluoxetine, 20 ng/ml for paroxetine, 25 ng/ml for venlafaxine, norfluoxetine and citalopram, and its metabolites, 40 ng/ml for sertraline and 50 ng/ml for fluvoxamine. No interferences were noted with this sensitive and specific method which can be used for therapeutic drug monitoring. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:147 / 158
页数:12
相关论文
共 37 条
[1]   High-performance liquid chromatography method for analyzing citalopram and desmethylcitalopram from human serum [J].
Akerman, KK ;
Jolkkonen, J ;
Huttunen, H ;
Penttila, I .
THERAPEUTIC DRUG MONITORING, 1998, 20 (01) :25-29
[2]   Determination of fluoxetine and its metabolite norfluoxetine in serum and brain areas using high-performance liquid chromatography with ultraviolet detection [J].
Alvarez, JC ;
Bothua, D ;
Colignon, I ;
Advenier, C ;
Spreux-Varoquaux, O .
JOURNAL OF CHROMATOGRAPHY B, 1998, 707 (1-2) :175-180
[3]   Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors [J].
Baumann, P .
CLINICAL PHARMACOKINETICS, 1996, 31 (06) :444-469
[4]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION USED FOR LABORATORY ROUTINE DETERMINATION OF FLUVOXAMINE IN HUMAN PLASMA [J].
BELMADANI, A ;
COMBOURIEU, I ;
BONINI, M ;
CREPPY, EE .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1995, 14 (01) :34-37
[5]   DETERMINATION OF PAROXETINE IN HUMAN-PLASMA, USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
BRETT, MA ;
DIERDORF, HD ;
ZUSSMAN, BD ;
COATES, PE .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 419 :438-444
[6]   Are pharmacokinetic drug interactions with the SSRIs an issue? [J].
Brosen, K .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 :23-27
[7]   Metabolism of the newer antidepressants - An overview of the pharmacological and pharmacokinetic implications [J].
Caccia, S .
CLINICAL PHARMACOKINETICS, 1998, 34 (04) :281-302
[8]   Solid-phase extraction with end-capped C2 columns for the routine measurement of racemic citalopram and metabolites in plasma by high-performance liquid chromatography [J].
Carlsson, B ;
Norlander, B .
JOURNAL OF CHROMATOGRAPHY B, 1997, 702 (1-2) :234-239
[9]  
Charlier C, 1997, Rev Med Liege, V52, P336
[10]  
CHARLIER C, 1997, TOXICORAMA